Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENGN Stock Forecast 2026-2027
$8.51
Current Price
$570.08M
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ENGN Price Targets
+252.5%
To High Target of $30.00
+193.8%
To Median Target of $25.00
+5.8%
To Low Target of $9.00
ENGN Price Momentum
+9.7%
1 Week Change
+18.0%
1 Month Change
+112.8%
1 Year Change
-5.8%
Year-to-Date Change
-30.5%
From 52W High of $12.25
+221.1%
From 52W Low of $2.65
📊 TOP ANALYST CALLS
Did ENGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if enGene is one of their latest high-conviction picks.
Latest ENGN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ENGN has a bullish consensus with a median price target of $25.00 (ranging from $9.00 to $30.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $8.51, the median forecast implies a 193.8% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Leland Gershell at Oppenheimer, projecting a 252.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENGN Analyst Ratings
9
Buy
1
Hold
0
Sell
ENGN Price Target Range
Low
$9.00
Average
$25.00
High
$30.00
Current: $8.51
Latest ENGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 13, 2026 | WBB Securities | Karen Sterling | Buy | Initiates | $21.50 |
| Mar 11, 2026 | Oppenheimer | Leland Gershell | Outperform | Maintains | $30.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $25.00 |
| Nov 12, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $19.00 |
| Nov 12, 2025 | UBS | Colin Bristow | Neutral | Maintains | $10.00 |
| Nov 12, 2025 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $33.00 |
| Nov 12, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $21.00 |
| Sep 12, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $18.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $25.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Reiterates | $25.00 |
| Apr 29, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $18.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Andres Maldonado | Buy | Reiterates | $25.00 |
| Mar 11, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $34.00 |
| Feb 18, 2025 | Piper Sandler | Allison Bratzel | Overweight | Initiates | $26.00 |
| Feb 14, 2025 | UBS | Colin Bristow | Neutral | Downgrade | $7.00 |
| Dec 23, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $18.00 |
| Dec 23, 2024 | HC Wainwright & Co. | Andres Maldonado | Buy | Initiates | $25.00 |
| Dec 6, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $18.00 |
| Nov 27, 2024 | Raymond James | Sean McCutcheon | Outperform | Initiates | $23.00 |
| Nov 18, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $18.00 |
Engene Holdings Inc. (ENGN) Competitors
The following stocks are similar to enGene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Engene Holdings Inc. (ENGN) Financial Data
Engene Holdings Inc. has a market capitalization of $570.08M with a P/E ratio of -3.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -46.1%.
Valuation Metrics
Market Cap
$570.08M
Enterprise Value
$327.60M
P/E Ratio
-3.7x
PEG Ratio
0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+48.4%
Current Ratio
11.8x
Debt/Equity
11.9x
ROE
-46.1%
ROA
-25.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Engene Holdings Inc. (ENGN) Business Model
About Engene Holdings Inc.
What They Do
Develops advanced biopharmaceutical technologies.
Business Model
The company focuses on enhancing drug delivery systems that improve the efficacy and safety of pharmaceuticals. It generates revenue through the commercialization of its proprietary methodologies and delivery platforms, which transform oral and injectable drugs for various medical conditions.
Additional Information
Engene Holdings Inc. operates in a highly regulated healthcare sector and plays a crucial role in advancing healthcare solutions. Its innovations address unmet medical needs, improve patient outcomes, and have the potential for cost-efficient health interventions. The company's strategic partnerships and commitment to R&D position it as a leader in therapeutic advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
81
CEO
Mr. Ronald H. W. Cooper
Country
Canada
IPO Year
2023
Website
www.engene.comEngene Holdings Inc. (ENGN) Latest News & Analysis
Latest News
Quick Summary
enGene Therapeutics Inc. will change its corporate name on April 8, 2026, to reflect its transition to a commercial organization ahead of potential drug approval in 2027.
Why It Matters
enGene's name change signals a strategic shift towards commercialization, potentially enhancing its market perception and attracting investor interest ahead of a key product approval.
Source: Business Wire
Market Sentiment:
Neutral
enGene Holdings: Key Catalysts Incoming For 2026
1 month ago
Quick Summary
enGene Holdings maintains a 'Buy' rating, bolstered by positive clinical data for detalimogene voraplasmid, which showed a 63% response rate. A BLA submission is expected in H2 2026.
Why It Matters
Promising clinical data and strong financials position enGene Holdings favorably. A potential FDA approval in 2026 could drive stock value, attracting investor interest.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
enGene Holdings Inc. reported its Q1 financial results for the period ending January 31, 2026. The company anticipates updates on clinical data from its LEGEND study at an upcoming spring medical conference.
Why It Matters
enGene's financial results and updates on pivotal clinical trials are crucial for assessing potential growth, risks, and investment opportunities in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
enGene Holdings Inc. (ENGN) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key developments and insights relevant to investors.
Why It Matters
The presentation at a major healthcare conference signals enGene's visibility and potential growth, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
enGene Holdings Inc. will participate in the Oppenheimer Healthcare Conference on February 26, 2026, at 1:20 p.m. ET and the Leerink Partners Conference on March 9, 2026, at 8:00 a.m. ET.
Why It Matters
enGene's participation in major investor conferences signals potential visibility and interest in its genetic medicine developments, which may influence stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
enGene Holdings Inc. CEO Ron Cooper will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. A live webcast will be available on their website.
Why It Matters
The CEO's participation in a prominent biotech summit highlights enGene's visibility and potential, which could influence investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ENGN Stock
What is Engene Holdings Inc.'s (ENGN) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Engene Holdings Inc. (ENGN) has a median price target of $25.00. The highest price target is $30.00 and the lowest is $9.00.
Is ENGN stock a good investment in 2026?
According to current analyst ratings, ENGN has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENGN stock?
Wall Street analysts predict ENGN stock could reach $25.00 in the next 12 months. This represents a 193.8% increase from the current price of $8.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Engene Holdings Inc.'s business model?
The company focuses on enhancing drug delivery systems that improve the efficacy and safety of pharmaceuticals. It generates revenue through the commercialization of its proprietary methodologies and delivery platforms, which transform oral and injectable drugs for various medical conditions.
What is the highest forecasted price for ENGN Engene Holdings Inc.?
The highest price target for ENGN is $30.00 from Leland Gershell at Oppenheimer, which represents a 252.5% increase from the current price of $8.51.
What is the lowest forecasted price for ENGN Engene Holdings Inc.?
The lowest price target for ENGN is $9.00 from at , which represents a 5.8% increase from the current price of $8.51.
What is the overall ENGN consensus from analysts for Engene Holdings Inc.?
The overall analyst consensus for ENGN is bullish. Out of 12 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are ENGN stock price projections?
Stock price projections, including those for Engene Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 8:01 AM UTC